Genomenon, Inc spotlighted Project Manager Betty Mathias for five years.

The Real-world Evidence to validate a drug target, identify trial-eligible patients, or change a diagnosis already exists. It is published. It is peer-reviewed. It is buried in 39 million biomedical articles, locked behind paywalls, hidden in tables, appendices, and supplemental datasets that most researchers and clinicians never find. Missing that evidence has consequences. Rare disease patients go undiagnosed. Cancer patients miss life-saving treatments built around variants their lab could not classify. Drug programs commit to development paths on incomplete data. Clinical trials miss eligible patients. Label expansions get left on the table. Genomenon was founded to close that gap. Fit-for-purpose AI-powered search indexes the 11.2 million full-text papers and 3.7 million supplemental tables and datasets standard tools miss. Eighty expert scientific curators review and validate every finding. The result is structured, traceable, regulatory-grade Real-World Evidence at the genetic variant and patient level. The difference is measured. Loxo@Lilly used Genomenon to expand the Retevmo label by 73 variants, broadening medullary thyroid cancer eligibility by 15%. Amicus added 1,300+ GLA variants for Fabry disease, with 534 deposited in ClinVar, expanding the Galafold label by 15 variants. In a published head-to-head, Genomenon identified 83% more PRKAG2 cardiomyopathy patients than ChatGPT plus OpenEvidence. More than 250 diagnostic labs and 75 biopharma programs rely on Genomenon today as the evidence layer behind precision medicine. We find the Real-World Evidence that changes rare disease and cancer patients’ lives.

Founded 2014